Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations

NCT00989261 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00989261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00989261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
December 31, 2014
Enrollment
333 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia